Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
Public ClinicalTrials.gov record NCT00005958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim
Study identification
- NCT ID
- NCT00005958
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- Not listed
Conditions and interventions
Interventions
- docetaxel Drug
- filgrastim Biological
- gemcitabine hydrochloride Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 1999
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Dec 3, 2013
Started 1999
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego | La Jolla | California | 92093 | — |
| Sacramento Center for Hematology and Medical Oncology | Sacramento | California | 95819 | — |
| Washington Cancer Institute | Washington D.C. | District of Columbia | 20010 | — |
| Center for Hematology-Oncology | Boca Raton | Florida | 33486 | — |
| Oncology-Hematology Associates of North Illinois, Ltd. | Gurnee | Illinois | 60031 | — |
| Maine Center for Cancer Medicine and Blood Disorders | Scarborough | Maine | 04074 | — |
| St. Joseph Medical Center | Towson | Maryland | 21204 | — |
| Hematology & Oncology Associates of Southern Michigan | Jackson | Michigan | 49201 | — |
| Hematology Oncology Associates of Central New York | Syracuse | New York | 13217-6962 | — |
| Memphis Cancer Center, Inc. | Memphis | Tennessee | 38119 | — |
| Arlington Cancer Center | Arlington | Texas | 76012 | — |
| Northern Virginia Oncology Group | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00005958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2013 · Synced May 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00005958 live on ClinicalTrials.gov.